Trevena Inc (NASDAQ:TRVN)’s share price was down 1.9% during mid-day trading on Tuesday . The company traded as low as $1.52 and last traded at $1.57. Approximately 688,272 shares were traded during trading, a decline of 21% from the average daily volume of 872,977 shares. The stock had previously closed at $1.54.
A number of equities analysts recently issued reports on TRVN shares. Oppenheimer set a $5.00 price objective on shares of Trevena and gave the stock a “buy” rating in a research report on Monday, March 12th. Zacks Investment Research cut shares of Trevena from a “buy” rating to a “hold” rating and set a $2.00 price objective for the company. in a research report on Saturday, January 20th. Finally, HC Wainwright upped their price objective on shares of Trevena to $7.00 and gave the stock a “buy” rating in a research report on Thursday, March 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $7.06.
The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.71 and a current ratio of 3.71. The stock has a market cap of $103.11, a PE ratio of -1.32 and a beta of -0.52.
Trevena (NASDAQ:TRVN) last announced its quarterly earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.02. equities research analysts forecast that Trevena Inc will post -0.89 EPS for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Millennium Management LLC acquired a new position in Trevena in the 4th quarter valued at approximately $130,000. American Century Companies Inc. acquired a new position in Trevena in the 4th quarter valued at approximately $135,000. California State Teachers Retirement System increased its position in Trevena by 0.5% in the 2nd quarter. California State Teachers Retirement System now owns 97,107 shares of the biopharmaceutical company’s stock valued at $223,000 after acquiring an additional 500 shares during the period. Bourgeon Capital Management LLC increased its position in Trevena by 59.3% in the 4th quarter. Bourgeon Capital Management LLC now owns 137,800 shares of the biopharmaceutical company’s stock valued at $220,000 after acquiring an additional 51,300 shares during the period. Finally, Virtu Financial LLC increased its position in Trevena by 1,546.1% in the 4th quarter. Virtu Financial LLC now owns 191,701 shares of the biopharmaceutical company’s stock valued at $307,000 after acquiring an additional 180,055 shares during the period. Hedge funds and other institutional investors own 50.47% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Trevena (TRVN) Trading Down 1.9%” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/04/05/trevena-trvn-trading-down-1-9.html.
Trevena Company Profile
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.